FDA approves Rybelsus, the first oral GLP-1 receptor agonist

The U.S. Food and Drug Administration approved Rybelsus (semaglutide) tablets on September 20, 2019, for adults with type 2 diabetes ^[1][6]. It was the first GLP-1 receptor agonist available as a pill rather than an injection ^[1]. The FDA reviewed the application, NDA 213051, under priority review ^[6].

Rybelsus came from Novo Nordisk, the same company that makes semaglutide injections ^[1]. Ozempic, the once-weekly injectable version of semaglutide, had been approved nearly two years earlier, on December 5, 2017 ^[4]. The tablet was cleared as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes ^[1].

How the pill works and how it is taken

Semaglutide is an analog of the natural hormone GLP-1. It binds to and activates the GLP-1 receptor, stimulating insulin release and lowering glucagon secretion when blood glucose is high ^[1]. Semaglutide is a peptide, which normally would be broken down in the stomach. To get it across, the tablet is co-formulated with an absorption enhancer called SNAC — sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, also known as salcaprozate sodium ^[2].

That formulation is why the label is unusually specific about timing. The tablet is taken once daily in the morning on an empty stomach with no more than 4 ounces of water, and no other liquids ^[5]. Tablets are swallowed whole, not split, crushed, chewed or dissolved ^[5]. After taking it, the label directs waiting at least 30 minutes before eating food, drinking other beverages, or taking other oral medications ^[5].

Rybelsus was approved in 3 mg, 7 mg and 14 mg tablets ^[1]. Under the labeled schedule, the 3 mg strength is used for the first 30 days and is described in the prescribing information as not effective for glycemic control on its own; the dosage is then increased, with a further step possible on day 61 or later ^[5].

The clinical program behind the approval was called PIONEER ^[2]. European regulators, who received a parallel application on April 26, 2019, questioned why 14 mg was chosen as the top dose, noting that in earlier testing 40 mg had a markedly stronger effect on HbA1c than 10 mg ^[2].

The most common side effects reported at a rate of 5% or higher are nausea, abdominal pain, diarrhea, decreased appetite, vomiting and constipation ^[1][5]. The current prescribing information carries a boxed warning about the risk of thyroid C-cell tumors seen in rodents, and the product is contraindicated in people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2 ^[5]. A separate drug reference summary of Rybelsus lists warnings including acute pancreatitis, diabetic retinopathy complications, hypoglycemia when combined with insulin or insulin secretagogues, acute kidney injury from volume depletion, severe gastrointestinal reactions, hypersensitivity, and pulmonary aspiration during anesthesia, without listing a boxed warning ^[1]; the prescribing information does include one ^[5].

Why it matters for patients

Before this approval, every GLP-1 medicine required an injection. A daily tablet removes needles from the equation for people who want that, but it trades weekly dosing for a daily routine with fixed rules about water, food and other pills ^[5].

Those rules are not optional details — absorption depends on them, which is why the label limits the amount of water and requires a 30-minute wait before anything else, including other oral medications ^[5]. The label also notes that semaglutide tablets delay gastric emptying, and suggests increased monitoring when taken with oral drugs that have a narrow therapeutic index ^[5].

The 2019 approval covered blood sugar control in type 2 diabetes only. It did not cover weight loss; a semaglutide injection for weight reduction, Wegovy, was not approved until June 4, 2021 ^[1].

What happened next

• January 12, 2023: FDA approved a label update allowing Rybelsus as a first-line option for adults with type 2 diabetes ^[1].
• December 9, 2024: FDA approved a second tablet formulation in 1.5 mg, 4 mg and 9 mg strengths ^[1].
• October 17, 2025: FDA approved Rybelsus to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk ^[1][6].
• January 30, 2026: FDA approved a labeling change renaming that newer tablet formulation to Ozempic (semaglutide) tablets ^[1]. The two tablet lines are not substitutable on a milligram-to-milligram basis ^[5].